ArticleThe oncologist2025
Clinicopathological and molecular characteristics and treatment outcomes of SMARCA4-deficient thoracic tumors: a comprehensive analysis.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Establishment and characterization of TRI-LC21: a novel patient-derived cell line of SMARCA4-deficient undifferentiated thoracic tumor.Human cell · 2026Article
- Bibliometric analysis and knowledge mapping of thoracic SMARCA4-deficient undifferentiated tumor.Discover oncology · 2026Article
- Distinct multiplex immunofluorescence-based immune and stromal marker expression profile of subcutaneously metastatic SMARCA4-deficient undifferentiated thoracic tumor: a case report.Translational lung cancer research · 2026Article
- SMARCA4-deficient lung adenocarcinoma with oral cavity metastasis: a case report.BMC oral health · 2026Article
- SMARCA4-deficient non-small cell lung cancer and immunotherapy resistance: mechanisms and novel strategies-a mini-review.Discover oncology · 2026Review
- CT imaging features of pulmonary SMARCA4-deficient undifferentiated carcinoma: a retrospective case series.Frontiers in oncology · 2026Article
- CDK4/6 inhibition with dual immunotherapy in chemorefractory SMARCA4-deficient undifferentiated tumor: a case report.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveSMARCA4-deficient thoracic tumors (SDTTs) mainly include SMARCA4-deficient undifferentiated thoracic tumor (SMARCA4-dUT) and SMARCA4-deficient non-small cell lung cancer (SMARCA4-dNSCLC). Comparative studies between these subtypes remain limited, and no standardized therapeutic guidelines have been established.
designThis study retrospectively analyzed 102 patients with SDTT from January 2020 to May 2024. We evaluated the efficacy of different treatments for SDTT and compared the clinicopathological features and prognostic outcomes between SD-UT and SD-NSCLC.
resultsSDTT predominantly occurs in older male smokers. SMARCA4-dUT exhibits high NSE expression, higher risk of lymph node metastases, and lower rates of early diagnosis than SMARCA4-dNSCLC. SMARCA4-dNSCLC can be distinguished from SMARCA4-dUT by gland architecture and the diffuse expression of epithelial markers, whereas SMARCA4-dUT shows positive expression for Syn and stem cell markers. Common mutations include TP53, SMARCA4, KRAS, and STK11, with STK11/KRAS co-mutations associated with poorer prognosis. SMARCA4 protein loss was observed not only in class I mutations but also in class II mutations and wild-type cases. Both SMARCA4-dUT and SMARCA4-dNSCLC carry a high recurrence risk after radical treatment. Immune-based therapy significantly improved median progression-free survival (mPFS) and overall survival (mOS) compared with non-immunotherapy (mPFS, 8.6 vs. 3.3 months, P < .0001; mOS, 13.1 vs. 8.0 months, P = .048). Central nervous system metastasis, pleura metastasis, and primary tumor resection were independent factors for OS.
conclusionsThis study provides a comprehensive analysis of SDTT to date, based on a relatively large sample size. STK11/KRAS co-mutations are associated with poorer prognosis. SMARCA4-dNSCLC can be distinguished from SMARCA4-dUT by epithelial markers and stem cell markers. Immune-based therapy is the optimal option in the current treatment strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.